Sanofi
Sanofi is one of the world’s leading vaccine companies and a major participant in immunology. Its vaccine business, historically associated with Sanofi Pasteur, spans influenza, pediatric vaccines, meningococcal disease, travel vaccines, and respiratory disease prevention.
- Highest 2026 tier: Tier I
- Vaccine & Immunotherapy Developers
- 2 ranking categories
Overview
Sanofi is one of the world’s leading vaccine companies and a major participant in immunology. Its vaccine business, historically associated with Sanofi Pasteur, spans influenza, pediatric vaccines, meningococcal disease, travel vaccines, and respiratory disease prevention.
Sanofi’s strength lies in its combination of vaccine manufacturing, public health relevance, and immunology expertise. The company remains one of the traditional global vaccine leaders and is consistently identified among the major vaccine manufacturers worldwide.
Sanofi is included in 2 2026 ranking categories. Its highest classification is Tier I. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | Sanofi |
| Business heritage / current legal entity | 1973 Sanofi heritage; 1994 incorporation; 2004 Sanofi-Aventis combination |
| Institution type | Vaccine & Immunotherapy Developers institution |
| Headquarters | Paris, France |
| Primary focus | Vaccine & Immunotherapy Developers |
| Highest 2026 ranking tier | Tier I |
Contents
- Principal activities
- Sector and mandate coverage
- Market position
- Competitive context
- Leadership and governance
- Corporate and public information
- Additional published ranking appearances
- Rankings and recognition
- Related Economy analysis
- Related institutions and subjects
- Sources and data transparency
- Rankings and recognition — 2027
- Explore The Economy
Principal activities
Sanofi’s strength lies in its combination of vaccine manufacturing, public health relevance, and immunology expertise. The company remains one of the traditional global vaccine leaders and is consistently identified among the major vaccine manufacturers worldwide.
Core capability
Vaccine & Immunotherapy Developers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Vaccine & Immunotherapy Developers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
The company’s vaccine scale, influenza and pediatric vaccine portfolio, immunology strength, global access infrastructure, and manufacturing capability support its position among the leading vaccine and immunotherapy developers.
Sanofi is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier I.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Sanofi should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Sanofi. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Sanofi |
| Headquarters | Paris, France |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Additional published ranking appearances
These entries retain the edition, classification and assessed business name published in the source. Historical entries describe that edition, including businesses whose ownership or name later changed.
| Published ranking | Edition / tier | Assessed business |
|---|---|---|
| Top 20 Vaccine & Immunotherapy Developers 2025 | 2025 · Tier I | Sanofi |
| Top 20 Global Pharmaceutical Companies 2025 | 2025 · Tier II | Sanofi |
| Top 20 Vaccine & Immunotherapy Developers 2024 | 2024 · Tier I | Sanofi |
| Top 20 Global Pharmaceutical Companies 2024 | 2024 · Tier II | Sanofi |
| Top 20 Vaccine & Immunotherapy Developers 2023 | 2023 · Tier I | Sanofi |
| Top 20 Global Pharmaceutical Companies 2023 | 2023 · Tier II | Sanofi |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Vaccine & Immunotherapy Developers 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Global Pharmaceutical Companies 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
Corrections and Updates
Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.
Rankings and recognition — 2027
Recorded appearances in The Economy Rankings. Each entry concerns the assessed business, product, institution or workforce scope in the linked edition.
| Ranking | Edition / classification | Assessed scope |
|---|---|---|
| Employers for Internal Career Mobility | 2027 · Tier I · position 5 | Direct employees in the documented internal career pathways; external recruits, customers and contractors excluded. |
| Employers for Workforce Reskilling | 2027 · Tier III | Direct employees in the documented programme or operating population; country, role and eligibility conditions retained. |
| Employers for Employee Benefits | 2027 · Tier III | UK direct employees; published global programme commitments only; local variations retained; contractors excluded |
| Employers for Healthcare Benefits | 2027 · Tier II | UK direct employees; published global programme commitments only; local variations retained; contractors excluded |
| Employers for Mental Health Support | 2027 · Tier II | UK direct employees; published global programme commitments only; local variations retained; contractors excluded |
| Employers for Parental Leave | 2027 · Tier III | Great Britain employees covered by the published policy; contractors excluded |
| Employers for Family-Friendly Benefits | 2027 · Tier II | UK direct employees; published global programme commitments only; local variations retained; contractors excluded |
| Employers for Employee Wellbeing | 2027 · Tier II | UK direct employees; published global programme commitments only; local variations retained; contractors excluded |
| Employers for Employee Participation | 2027 · Tier II | Direct employees in the documented programme or operating population; country, role and eligibility conditions retained. |
Explore The Economy
The following articles provide wider sector context. They are not necessarily coverage of this specific entity or an endorsement by it.
Sanofi’s 1973 heritage, the current company’s French incorporation in 1994 and the Sanofi-Aventis combination in 2004 are separate milestones. On 30 April 2025, the Opella transaction closed: CD&R acquired a 50.0% controlling stake, Sanofi retained 48.2% and Bpifrance held 1.8%. The assessed medicines and vaccine businesses must not be conflated with the separated consumer-healthcare company. References: Nossa história; Sanofi prospectus; Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader.